ResMed CFO Aaron Bloomer Earns 9,072 Performance-Based RSUs

Executive Summary

On October 1, 2026, ResMed Inc. ($RMD) filed a Form 4 disclosing that Chief Financial Officer Aaron Bloomer acquired 9,072 shares of ResMed Common Stock on August 14, 2026. This acquisition was an award (Transaction Code 'A') at $0 per share, reflecting performance-based restricted stock units (RSUs) earned upon certification of performance metrics.

Transaction Details

• Insider: Aaron Bloomer, Chief Financial Officer
• Security: ResMed Common Stock
• Date of Transaction: August 14, 2026
• Transaction Code: A (Award/Grant)
• Shares Acquired: 9,072 shares
• Price: $0.00 per share
• Post-Transaction Beneficial Ownership: 9,072 direct shares
• Footnote Context: Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were officially earned on August 14, 2026, following the compensation and leadership development committee's certification that applicable performance metrics were met. The RSUs vest in one-third increments annually on the anniversary of the grant.

Trading Significance

This filing carries Low trading significance. It represents routine executive equity compensation resulting from performance metric certification rather than an open-market purchase or sale. As such, it does not provide discretionary directional signaling regarding the company's near-term outlook.